1
|
Utpat N, Annam R, Kargutkar-Ajgaonkar S. The Uncharted Link Between Desogestrel and Hypercalcemia. Cureus 2023; 15:e40577. [PMID: 37465813 PMCID: PMC10351965 DOI: 10.7759/cureus.40577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2023] [Indexed: 07/20/2023] Open
Abstract
This report presents a unique case of hypercalcemia with an elusive etiology. A 37-year-old Caucasian female with a history of gonadotropin-secreting pituitary microadenoma and recurrent nephrolithiasis was found to have hypercalcemia, hypercalciuria, elevated 1,25-dihydroxyvitamin D levels, and low parathyroid hormone levels. Extensive investigations were conducted to identify the cause, including ruling out sarcoidosis and other granulomatous disorders. Imaging and diagnostic testing revealed normal results. The patient's condition considerably improved after the cessation of an oral contraceptive pill containing desogestrel. This surprising association raises the possibility that the use of desogestrel could result in hypercalcemia as one of the side effects. To ensure proper care and avoid consequences linked to severe hypercalcemia, a high index of suspicion is needed to detect the underlying cause of hypercalcemia, even in the absence of usual indications.
Collapse
Affiliation(s)
- Nishka Utpat
- Research, Rutgers Health/Community Medical Center, Toms River, USA
| | - Radhika Annam
- Endocrinology, Diabetes, and Metabolism, Hospital Sisters Health System Medical Group, Effingham, USA
| | | |
Collapse
|
2
|
Regidor PA, Colli E. The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia. Gynecol Endocrinol 2022; 38:978-982. [PMID: 36265507 DOI: 10.1080/09513590.2022.2134339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
INTRODUCTION Dysmenorrhea and mastodynia are the most common gynecologic pain causes in women of all ages and races during their reproductive life. The following study aimed to show the influence of two POP´s in the development of dysmenorrhea and mastodynia after nine months of use. MATERIAL AND METHODS A total of 858 women with 6691 drospirenone (DRSP) cycles and 332 women with 2487 desogestrel (DSG) cycles were analyzed. Women included in this study were all child-bearing potentials, at risk of pregnancy, agreeing to use only the study medication for contraception for the duration of the study medication treatment, aged 18 to 45. RESULTS At screening, 168 (19.6%) of the 858 patients using DRSP and 64 (19,3%) of the DSG patients reported that they had suffered from dysmenorrhea within six cycles prior to the first visit before starting with the medication. 20,2% of the DRSP and 10,9% of the DSG group had a sever dysmenorrhea. After 9 cycles this was reduced to 0,6% and 3,1% respectively. In total, 96 women (11.2%) in the DRSP and 49 (14,8%) experienced mastodynia within six cycles before the screening. Of these 91.6% in the DRSP group and 91,8% in the DSG group had no or mild mastodynoa at follow-up. DISCUSSION The progestins 4 mg and desogestrel 0,075 mg showed a marked effect in the non-contraceptive aspects of dysmenorrhea and mastodynia so that new possibilities are opened for these two benign gynecological diseases. Future studies must reaffirm these first data.
Collapse
|
3
|
Vannuccini S, Biagiotti C, Esposto MC, La Torre F, Clemenza S, Orlandi G, Capezzuoli T, Petraglia F. Long-term treatment of endometriosis-related pain among women seeking hormonal contraception. Gynecol Endocrinol 2022; 38:398-402. [PMID: 35238265 DOI: 10.1080/09513590.2022.2047172] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
OBJECTIVE To evaluate the different effects of a progestin-only contraceptive with desogestrel (DSG) vs combined oral contraceptives (COCs) for a first line long-term treatment of endometriosis-related pain among patients seeking hormonal contraception. METHODS An observational retrospective cohort study was conducted in collaboration with a local outpatient clinic for endometriosis among a group of nulliparous young women (n = 216) with endometriosis-related pain and seeking contraception. The cohort was subdivided into a group (n = 73) treated as first line by DSG and another group (n = 75) treated by a COC. During the study, clinical symptoms, side effects and possible changes in OC type use were recorded. RESULTS No significant difference was found between the two groups in terms of clinical characteristics and pain scores before treatment. After 6 months both treatments were effective in reducing endometriosis-related pain, and those treated with DSG showed lower levels of dysmenorrhea, dyspareunia and nonmenstrual pelvic pain than COCs group (p < .01). After 12 months, in DSG Group some patients (15%) switched from DSG to a COC for breakthrough bleeding, whereas in COC Group 48% of patients switched to another type of COC for reduced efficacy on pain and/or for side effects. After 3 years of OC treatment, in DSG Group 79% of patients maintained the same therapy, whereas in COC Group only 14% continued the same COC type, 37% switched to another COC and 47% to DSG. CONCLUSIONS A progestin-only contraceptive with DSG is a valid option for long term management of endometriosis-related pain in patients seeking hormonal contraception.
Collapse
Affiliation(s)
- Silvia Vannuccini
- Obstetrics and Gynecology Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Careggi University Hospital, Florence, Italy
| | - Chiara Biagiotti
- Obstetrics and Gynecology Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Careggi University Hospital, Florence, Italy
| | | | - Francesco La Torre
- Obstetrics and Gynecology Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Careggi University Hospital, Florence, Italy
| | - Sara Clemenza
- Obstetrics and Gynecology Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Careggi University Hospital, Florence, Italy
| | - Gretha Orlandi
- Obstetrics and Gynecology Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Careggi University Hospital, Florence, Italy
| | - Tommaso Capezzuoli
- Obstetrics and Gynecology Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Careggi University Hospital, Florence, Italy
| | - Felice Petraglia
- Obstetrics and Gynecology Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Careggi University Hospital, Florence, Italy
| |
Collapse
|
4
|
Matasariu DR, Lozneanu L, Dumitraşcu I, Grigore M, Cristofor AE, Mandici CE, Bujor IE, Ursache A, Brăila AD, Bauşic A, Micu R. Hormonal, apoptotic, proliferative and inflammatory markers' expression in Desogestrel-treated women with ovarian endometriosis. Rom J Morphol Embryol 2022; 63:137-144. [PMID: 36074677 PMCID: PMC9593118 DOI: 10.47162/rjme.63.1.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/17/2022] [Accepted: 08/28/2022] [Indexed: 06/15/2023]
Abstract
Endometriosis is a relatively frequent pathology in gynecological practice. We performed an analysis to demonstrate the molecular changes that occur in endometriosis synthetic progestin-treated patients, hoping to sketch a possible pathophysiological pathway that will help us to better understand and treat this debilitating disease. We conducted a prospective study that included a group of 40 women, evaluated in our hospital between 2020-2021. We evaluated immunohistochemical tissue expression of estrogen receptor (ER), progesterone receptor (PR), B-cell lymphoma 2 (Bcl-2) protein, Ki-67, and serum levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) in patients with ovarian endometrioma with and without progestin treatment. Our study revealed that Desogestrel treatment increases OPN serum levels, PR and Bcl-2 tissue expression and reduces VEGF serum levels and Ki-67 tissue expression. The results we have obtained are very interesting because the serum levels of OPN seem to be more influenced by progestin treatment, than by endometriosis itself. The study we have conducted gives a molecular complex view of what endometriosis represents and on how Desogestrel treatment works.
Collapse
Affiliation(s)
- Daniela-Roxana Matasariu
- Department of Mother and Child, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
- Department of Obstetrics and Gynecology, Cuza Vodă Hospital, Iaşi, Romania
| | - Ludmila Lozneanu
- Department of Morpho-Functional Sciences I – Histology, Pathology, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
- Department of Pathology, Sf. Spiridon Emergency County Hospital, Iaşi, Romania
| | - Irina Dumitraşcu
- Department of Mother and Child, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
- Department of Obstetrics and Gynecology, Cuza Vodă Hospital, Iaşi, Romania
| | - Mihaela Grigore
- Department of Mother and Child, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
- Department of Obstetrics and Gynecology, Cuza Vodă Hospital, Iaşi, Romania
| | - Alexandra Elena Cristofor
- Department of Mother and Child, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
- Department of Obstetrics and Gynecology, Cuza Vodă Hospital, Iaşi, Romania
| | - Cristina Elena Mandici
- Department of Mother and Child, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
| | - Iuliana-Elena Bujor
- Department of Mother and Child, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
- Department of Obstetrics and Gynecology, Cuza Vodă Hospital, Iaşi, Romania
| | - Alexandra Ursache
- Department of Mother and Child, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania
| | - Anca Daniela Brăila
- Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, Romania
- Department of Obstetrics and Gynecology, Emergency County Hospital, Craiova, Romania
| | - Alexandra Bauşic
- Department of Obstetrics and Gynecology, Prof. Dr. Panait Sîrbu Hospital, Bucharest, Romania
| | - Romeo Micu
- Department of Obstetrics and Gynecology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- Department of Obstetrics and Gynecology, Regina Maria Maternity, Cluj-Napoca, Romania
| |
Collapse
|
5
|
Di Lascio S, Benfante R, Cardani S, Fornasari D. Research Advances on Therapeutic Approaches to Congenital Central Hypoventilation Syndrome (CCHS). Front Neurosci 2021; 14:615666. [PMID: 33510615 PMCID: PMC7835644 DOI: 10.3389/fnins.2020.615666] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 12/17/2020] [Indexed: 12/11/2022] Open
Abstract
Congenital central hypoventilation syndrome (CCHS) is a genetic disorder of neurodevelopment, with an autosomal dominant transmission, caused by heterozygous mutations in the PHOX2B gene. CCHS is a rare disorder characterized by hypoventilation due to the failure of autonomic control of breathing. Until now no curative treatment has been found. PHOX2B is a transcription factor that plays a crucial role in the development (and maintenance) of the autonomic nervous system, and in particular the neuronal structures involved in respiratory reflexes. The underlying pathogenetic mechanism is still unclear, although studies in vivo and in CCHS patients indicate that some neuronal structures may be damaged. Moreover, in vitro experimental data suggest that transcriptional dysregulation and protein misfolding may be key pathogenic mechanisms. This review summarizes latest researches that improved the comprehension of the molecular pathogenetic mechanisms responsible for CCHS and discusses the search for therapeutic intervention in light of the current knowledge about PHOX2B function.
Collapse
Affiliation(s)
- Simona Di Lascio
- Department of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy
| | - Roberta Benfante
- Department of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.,CNR-Institute of Neuroscience, Milan, Italy.,NeuroMi-Milan Center for Neuroscience, University of Milano Bicocca, Milan, Italy
| | - Silvia Cardani
- Department of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy
| | - Diego Fornasari
- Department of Medical Biotechnology and Translational Medicine (BIOMETRA), Università degli Studi di Milano, Milan, Italy.,CNR-Institute of Neuroscience, Milan, Italy
| |
Collapse
|
6
|
Fonseka S, Wijeyaratne CN, Gawarammana IB, Kalupahana NS, Rosairo S, Ratnatunga N, Kumarasiri R. Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/ Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study. J Clin Aesthet Dermatol 2020; 13:18-23. [PMID: 32983332 PMCID: PMC7492016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
BACKGROUND: The effectiveness of different combined oral contraceptive pills and metformin in reducing hirsutism in patients with polycystic ovary syndrome (PCOS) remains unclear. OBJECTIVE: We sought to determine the effects of ethinylestradiol (35μg)/cyproterone acetate (2mg) (EE/CPA) and ethinylestradiol (20μg)/desogestrel (0.15mg) (EE/DES), alone or with metformin, on hirsutism in PCOS. METHODS: A randomized, double-blind, triple-dummy study was conducted on women with PCOS and hirsutism (N=107) who received one of four drug combinations (Arm A: EE/CPA; Arm B: EE/DES; Arm C: EE/CPA plus metformin; or Arm D: EE/DES plus metformin). Hirsutism was assessed at baseline, six months, and 12 months by using five outcomes variables. RESULTS: No outcomes variable showed a significant difference between the four arms at 12 months. There was a significant reduction in both hair density and modified Ferriman-Gallwey score (mFGS) in Arm A, mFGS in Arm B, hair density in Arm C, and diameter of sideburn hair in Arm D, respectively. Separately, there was a significant increase noted in the hair growth rate of chin and an improvement in patients' perceptions of hirsutism in all four study arms. CONCLUSION: EE/CPA and EE/DES were equally effective in improving hirsutism in PCOS, with no added benefit from low-dose metformin. Sri Lanka Clinical Trials Registry (http://www.slctr.lk) registration no. SLCTR/2015/007.
Collapse
Affiliation(s)
- Sanjeewani Fonseka
- Dr. Fonseka is with the Department of Pharmacology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Wijeyaratne is with the Department of Obstetrics and Gynocology, Faculty of Medicine at the University of Colombo in Sri Lanka
- Dr. Gawarammana is with the Department of Medicine, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kalupahana is with the Department of Physiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Rosairo is with the Department of Radiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Ratnatunga is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kumarasiri is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
| | - Chandrika N Wijeyaratne
- Dr. Fonseka is with the Department of Pharmacology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Wijeyaratne is with the Department of Obstetrics and Gynocology, Faculty of Medicine at the University of Colombo in Sri Lanka
- Dr. Gawarammana is with the Department of Medicine, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kalupahana is with the Department of Physiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Rosairo is with the Department of Radiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Ratnatunga is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kumarasiri is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
| | - Indika B Gawarammana
- Dr. Fonseka is with the Department of Pharmacology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Wijeyaratne is with the Department of Obstetrics and Gynocology, Faculty of Medicine at the University of Colombo in Sri Lanka
- Dr. Gawarammana is with the Department of Medicine, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kalupahana is with the Department of Physiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Rosairo is with the Department of Radiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Ratnatunga is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kumarasiri is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
| | - Nishan S Kalupahana
- Dr. Fonseka is with the Department of Pharmacology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Wijeyaratne is with the Department of Obstetrics and Gynocology, Faculty of Medicine at the University of Colombo in Sri Lanka
- Dr. Gawarammana is with the Department of Medicine, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kalupahana is with the Department of Physiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Rosairo is with the Department of Radiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Ratnatunga is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kumarasiri is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
| | - Shanthini Rosairo
- Dr. Fonseka is with the Department of Pharmacology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Wijeyaratne is with the Department of Obstetrics and Gynocology, Faculty of Medicine at the University of Colombo in Sri Lanka
- Dr. Gawarammana is with the Department of Medicine, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kalupahana is with the Department of Physiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Rosairo is with the Department of Radiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Ratnatunga is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kumarasiri is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
| | - Neelakanthi Ratnatunga
- Dr. Fonseka is with the Department of Pharmacology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Wijeyaratne is with the Department of Obstetrics and Gynocology, Faculty of Medicine at the University of Colombo in Sri Lanka
- Dr. Gawarammana is with the Department of Medicine, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kalupahana is with the Department of Physiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Rosairo is with the Department of Radiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Ratnatunga is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kumarasiri is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
| | - Ranjith Kumarasiri
- Dr. Fonseka is with the Department of Pharmacology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Wijeyaratne is with the Department of Obstetrics and Gynocology, Faculty of Medicine at the University of Colombo in Sri Lanka
- Dr. Gawarammana is with the Department of Medicine, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kalupahana is with the Department of Physiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Rosairo is with the Department of Radiology, Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Ratnatunga is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
- Dr. Kumarasiri is with the Faculty of Medicine at the University of Peradeniya in Sri Lanka
| |
Collapse
|
7
|
Abstract
Compared with nonuse, combined hormonal contraceptives containing estrogen and a progestogen are associated with a roughly 2- to 3-fold increased risk of venous and a 2-fold increased risk of arterial thromboembolism, including stroke and acute myocardial infarction. These events are, however, overall rare among women of reproductive age. Historically, progestin-only pills were not thought to be linked with any thromboembolic risk increase. Therefore, these preparations may be valuable options in women who are ineligible to take combined hormonal contraceptives. Until recently, only progestogens with partial androgenic activities were available. As demonstrated in animal studies, more modern progestogens such as drospirenone with its anti-mineralocorticoid effects may be associated with even more favorable aspects, which have to be clinically demonstrated, however, in future studies.
Collapse
Affiliation(s)
- Christian Egarter
- Medical University Vienna, Department of Gynecological Endocrinology & Reproductive Medicine, Waehringer Guertel 18-201090 Vienna, Austria
| |
Collapse
|
8
|
Martínez F, Rodriguez-Purata J, Clua E, Garcia S, Coroleu B, Polyzos N. Ovarian response in oocyte donation cycles under LH suppression with GnRH antagonist or desogestrel progestin: retrospective and comparative study. Gynecol Endocrinol 2019; 35:884-889. [PMID: 31081407 DOI: 10.1080/09513590.2019.1604662] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Here are investigated the serum hormones in ovarian stimulation cycles of oocyte donors (OD), under endogenous luteinizing hormone (LH) suppression with GnRH antagonist (antGnRH) vs. desogestrel (DSG) (progesterone-primed [PP]). OD underwent ovarian stimulation with gonadotropins at a private, university-based, infertility center between January 2017 and March 2018. Endogenous LH peak was controlled with either daily injections of antGnRH or with daily oral 75 mcg DSG (PP) until triggering. LH and progesterone were measured at trigger and the following day. A total of 404 OD cycles were included. There were no differences in age (26.7 ± 4.9 vs. 27.1 ± 4.8 years), AMH (3.7 ± 2.1 vs. 4.1 ± 2.7 ng/ml), and body mass index (BMI) (22.4 ± 2.8 vs. 22.1 ± 3.0 kg/m2) between PP and antGnRH groups, respectively. On the day of trigger, progesterone was lower in PP compared to antGnRH (0.9 ± 0.7, vs. 1.5 ± 1.2 ng/ml, p < .001), whereas no significant differences existed in estradiol or LH. On the day after trigger, lower progesterone in PP vs. antGnRH (10.8 ± 6.0 vs. 13.4 ± 7.9 ng/ml, p=.002) was observed. No differences were observed in the number of retrieved oocytes or the clinical pregnancies among recipients. Our study shows that endocrine response to DSG differs significantly as compared to antGnRH use for the control of endogenous LH without apparent impact on number of retrieved oocytes or the clinical pregnancies among recipients.
Collapse
Affiliation(s)
- Francisca Martínez
- Hospital Universitari Dexeus, Reproductive Medicine Service, Barcelona, Spain
| | | | - Elisabet Clua
- Hospital Universitari Dexeus, Reproductive Medicine Service, Barcelona, Spain
| | - Sandra Garcia
- Hospital Universitari Dexeus, Reproductive Medicine Service, Barcelona, Spain
| | | | - Nikolaos Polyzos
- Hospital Universitari Dexeus, Reproductive Medicine Service, Barcelona, Spain
| |
Collapse
|
9
|
Merki-Feld GS, Imthurn B, Gantenbein AR, Sandor P. Effect of desogestrel 75 µg on headache frequency and intensity in women with migraine: a prospective controlled trial. EUR J CONTRACEP REPR 2019; 24:175-181. [PMID: 31094588 DOI: 10.1080/13625187.2019.1605504] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Objective: In contrast with combined hormonal contraception, progestin-only contraception is not associated with an increase in venous thromboembolism or stroke. Women with migraine are at increased risk of ischaemic stroke. Several studies have reported a reduction in migraine frequency and intensity with desogestrel 75 µg, a progestin-only pill. At present the quality of data is limited by retrospective study designs, lack of control groups and small sample sizes. We present the first prospective nonrandomised controlled trial. Methods: A total of 150 women with migraine visiting our clinic for contraceptive counselling were screened. The intervention group comprised women who opted for contraception with desogestrel (n = 98); the control group comprised women who continued their usual contraceptive (n = 36). Participants completed daily diaries for 90 days before the intervention and 180 days after the intervention. Results: In the intervention group, we found improvements in migraine frequency (p < .001), migraine intensity (p < .001) and the number of triptans used (p < .001). These improvements were already significant after 90 days of desogestrel use (p < .001). Disability scores also decreased significantly. No improvement was seen in the nonintervention group. Conclusion: These data demonstrate for the first time in a prospective controlled setting that daily use of the progestin desogestrel is associated with a decrease in migraine frequency, migraine intensity and pain medication use in women with migraine, with and without aura, who had previously been experiencing at least three days of migraine per month. Trial registration: The study is registered in the University of Zürich database ( www.research-projects.uzh.ch/unizh.htm ).
Collapse
Affiliation(s)
- Gabriele S Merki-Feld
- a Department of Reproductive Endocrinology , Zürich University Hospital , Zürich , Switzerland
| | - Bruno Imthurn
- b Department of Neurorehabilitation , RehaClinic , Bad Zurzach , Switzerland
| | | | - Peter Sandor
- b Department of Neurorehabilitation , RehaClinic , Bad Zurzach , Switzerland
| |
Collapse
|
10
|
Ginstman C, Frisk J, Carlsson B, Ärlemalm A, Hägg S, Brynhildsen J. Plasma concentrations of etonogestrel in women using oral desogestrel before and after Roux-en-Y gastric bypass surgery: a pharmacokinetic study. BJOG 2018; 126:486-492. [PMID: 30347490 DOI: 10.1111/1471-0528.15511] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/09/2018] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To investigate whether Roux-en-Y gastric bypass (RYGB) affects oral desogestrel (etonogestrel) pharmacokinetics. DESIGN Single centre, open label, phase-2 pharmacokinetic study. SETTING University hospital of Linköping, Sweden. POPULATION Fourteen women with planned RYGB surgery were included; nine women aged 18-45 years using 75 micrograms desogestrel completed the study. METHODS Steady-state etonogestrel pharmacokinetic (PK) parameters were measured on three occasions for each individual (at 8 ± 6 weeks before surgery, and at 12 ± 2 and 52 ± 2 weeks after surgery). Each patient served as her own control. On each occasion, serum samples were collected during a 24-hour period and etonogestrel concentrations were determined with ultra-performance liquid chromatography/tandem mass spectrometry. MAIN OUTCOME MEASURES Area under the plasma concentration time curve of etonogestrel (AUC0-24 hours ). RESULTS All women had significant postoperative weight loss. There were no significant differences in AUC0-24 hours , terminal half-lives (t½ ), time to peak serum concentrations (Tmax ), or apparent oral clearances of etonogestrel (CLoral ) before and after gastric bypass surgery on any occasion. Peak serum concentrations (Cmax ) increased after 52 ± 2 weeks compared with preoperative values (0.817 ng/ml versus 0.590 ng/ml, P = 0.024). CONCLUSION To our knowledge, this is the first study to investigate the effects on desogestrel pharmacokinetics after RYGB. This study did not reveal any clinically significant changes in etonogestrel pharmacokinetics, suggesting that oral desogestrel may be used by women after RYGB surgery. The sample size was limited, however, and therefore the results should be interpreted cautiously. TWEETABLE ABSTRACT The pharmacokinetics of oral desogestrel does not appear to change after gastric bypass surgery.
Collapse
Affiliation(s)
- C Ginstman
- Department of Obstetrics and Gynaecology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - J Frisk
- Department of Surgery and Department of Clinical and Experimental Medicine, Linköping University, Norrköping, Sweden
| | - B Carlsson
- Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
| | - A Ärlemalm
- Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
| | - S Hägg
- Futurum, Region Jönköping County, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
| | - J Brynhildsen
- Department of Obstetrics and Gynaecology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| |
Collapse
|
11
|
Loiseau C, Cayetanot F, Joubert F, Perrin-Terrin AS, Cardot P, Fiamma MN, Frugiere A, Straus C, Bodineau L. Current Perspectives for the use of Gonane Progesteronergic Drugs in the Treatment of Central Hypoventilation Syndromes. Curr Neuropharmacol 2018; 16:1433-1454. [PMID: 28721821 PMCID: PMC6295933 DOI: 10.2174/1570159x15666170719104605] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 06/30/2017] [Accepted: 07/12/2017] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Central alveolar hypoventilation syndromes (CHS) encompass neurorespiratory diseases resulting from congenital or acquired neurological disorders. Hypercapnia, acidosis, and hypoxemia resulting from CHS negatively affect physiological functions and can be lifethreatening. To date, the absence of pharmacological treatment implies that the patients must receive assisted ventilation throughout their lives. OBJECTIVE To highlight the relevance of determining conditions in which using gonane synthetic progestins could be of potential clinical interest for the treatment of CHS. METHODS The mechanisms by which gonanes modulate the respiratory drive were put into the context of those established for natural progesterone and other synthetic progestins. RESULTS The clinical benefits of synthetic progestins to treat respiratory diseases are mixed with either positive outcomes or no improvement. A benefit for CHS patients has only recently been proposed. We incidentally observed restoration of CO2 chemosensitivity, the functional deficit of this disease, in two adult CHS women by desogestrel, a gonane progestin, used for contraception. This effect was not observed by another group, studying a single patient. These contradictory findings are probably due to the complex nature of the action of desogestrel on breathing and led us to carry out mechanistic studies in rodents. Our results show that desogestrel influences the respiratory command by modulating the GABAA and NMDA signaling in the respiratory network, medullary serotoninergic systems, and supramedullary areas. CONCLUSION Gonanes show promise for improving ventilation of CHS patients, although the conditions of their use need to be better understood.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Laurence Bodineau
- Address correspondence to this author at the Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S1158 Neurophysiologie Respiratoire Expérimentale et Clinique, F-75013, Paris, France; Tel: 33 1 40 77 97 15; Fax: 33 1 40 77 97 89; E-mail:
| |
Collapse
|
12
|
Merki-Feld GS, Imthurn B, Dubey R, Sándor PS, Gantenbein AR. Improvement of migraine with change from combined hormonal contraceptives to progestin-only contraception with desogestrel: How strong is the effect of taking women off combined contraceptives? J OBSTET GYNAECOL 2017; 37:338-341. [PMID: 28129717 DOI: 10.1080/01443615.2016.1234438] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Migraine is a disabling headache disorder, which affects up to 17% of the female population. Oestrogen withdrawal during the menstrual cycle or the hormone-free interval in users of combined hormonal contraceptives (CHC) plays a pivotal role. Two diary-based studies demonstrated a positive impact of the progestin-only pill (POP) desogestrel 75 μg on the frequency of the migraine attacks and pain intensity. In both studies, CHC users as well as nonusers were included, which makes it difficult to distinguish between the effect of taking women off the CHC and the benefit of the POP itself. With the present study, we compared the therapeutic effect of the POP desogestrel 75 μg on migraine in current CHC users and nonusers. We found a positive influence of desogestrel on migraine not only in women who switched from CHCs to desogestrel, but also in those who had not used hormones over 6 months before starting it. Our findings need to be confirmed in prospectively conducted studies with larger sample size.
Collapse
Affiliation(s)
- Gabriele S Merki-Feld
- a Clinic for Reproductive Endocrinology, Department of Gynaecology and Obstetrics , University Hospital Zürich , Zurich , Switzerland
| | - Bruno Imthurn
- a Clinic for Reproductive Endocrinology, Department of Gynaecology and Obstetrics , University Hospital Zürich , Zurich , Switzerland
| | - Raghvendran Dubey
- a Clinic for Reproductive Endocrinology, Department of Gynaecology and Obstetrics , University Hospital Zürich , Zurich , Switzerland
| | - Peter S Sándor
- b Headache outpatient Clinic, Department of Neurorehabilitation , Reha Clinic Bad Zurzach & Baden , Bad Zurzach , Switzerland.,c Headache and Pain Unit, Department for Neurology , University Hospital Zürich , Zurich , Switzerland
| | - Andreas R Gantenbein
- b Headache outpatient Clinic, Department of Neurorehabilitation , Reha Clinic Bad Zurzach & Baden , Bad Zurzach , Switzerland.,c Headache and Pain Unit, Department for Neurology , University Hospital Zürich , Zurich , Switzerland
| |
Collapse
|
13
|
Bitzer J, Banal-Silao MJ, Ahrendt HJ, Restrepo J, Hardtke M, Wissinger-Graefenhahn U, Trummer D. Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/ desogestrel 150 μg (21/7 regimen). Int J Womens Health 2015; 7:501-9. [PMID: 26056491 PMCID: PMC4445871 DOI: 10.2147/ijwh.s77942] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Objective To assess whether the combined oral contraceptive (COC) ethinylestradiol (EE) 20 μg/drospirenone 3 mg taken in a 24/4-day regimen (ie, 4-day hormone-free interval) is more effective than an EE 20 μg/desogestrel (DSG) 150 μg COC taken in a 21/7-day regimen (ie, 7-day hormone-free interval) in reducing hormone withdrawal-associated symptoms (HWAS). Methods This double-blind, randomized study (NLM identifier: NCT01076582) was conducted at 34 centers in 12 countries. Otherwise healthy women who experienced ≥2 HWAS of headache, pelvic pain, and/or bloating when using their current COCs in a 21/7-day regimen were recruited. Subjects rated the severity of their HWAS daily on a seven-point Likert scale during a baseline cycle and during four 28-day cycles with EE/drospirenone 24/4 (n=290) or EE/DSG 21/7 (n=304). The primary variable was the mean change from baseline to cycle 4 in the composite HWAS score (sum of scores for all three symptoms) during cycle days 22–28. Results In the EE/drospirenone 24/4 group, the mean (standard deviation) composite HWAS score during cycle days 22–28 was reduced from 42.2 (24.8) at baseline to 12.8 (13.4) at cycle 4 (change from baseline: −30.3 [22.9]). In the EE/DSG 21/7 group, the corresponding value was reduced from 41.9 (25.8) to 14.3 (13.2) (change from baseline: −27.7 [24.8]), not significantly different versus EE/drospirenone 24/4. Bleeding pattern, treatment response, rescue medication use, compliance, quality of life, and tolerability were similar between treatments. Conclusion Both EE/drospirenone 24/4 and EE/DSG 21/7 reduced the composite HWAS score from baseline to cycle 4 in otherwise healthy women. The differences between treatments were too small to be statistically significant.
Collapse
Affiliation(s)
- Johannes Bitzer
- Department of Obstetrics and Gynecology, University Hospital of Basel, Basel, Switzerland
| | | | - Hans-Joachim Ahrendt
- Praxis für Frauenheilkunde, Klinische Forschung und Weiterbildung (Clinical Research and Further Education), Magdeburg, Germany
| | - Jaime Restrepo
- Centro de Investigación Clínica, Clinica Medellin Poblado, Medellin, Colombia
| | - Marion Hardtke
- Global Clinical Development Operations, Bayer Pharma AG, Berlin, Germany
| | | | - Dietmar Trummer
- Clinical Statistics Europe, Bayer Pharma AG, Berlin, Germany
| |
Collapse
|
14
|
Abstract
BACKGROUND Hirsutism occurs in 5% to 10% of women of reproductive age when there is excessive terminal hair growth in androgen-sensitive areas (male pattern). It is a distressing disorder with a major impact on quality of life. The most common cause is polycystic ovary syndrome. There are many treatment options, but it is not clear which are most effective. OBJECTIVES To assess the effects of interventions (except laser and light-based therapies alone) for hirsutism. SEARCH METHODS We searched the Cochrane Skin Group Specialised Register, CENTRAL (2014, Issue 6), MEDLINE (from 1946), EMBASE (from 1974), and five trials registers, and checked reference lists of included studies for additional trials. The last search was in June 2014. SELECTION CRITERIA Randomised controlled trials (RCTs) in hirsute women with polycystic ovary syndrome, idiopathic hirsutism, or idiopathic hyperandrogenism. DATA COLLECTION AND ANALYSIS Two independent authors carried out study selection, data extraction, 'Risk of bias' assessment, and analyses. MAIN RESULTS We included 157 studies (sample size 30 to 80) comprising 10,550 women (mean age 25 years). The majority of studies (123/157) were 'high', 30 'unclear', and four 'low' risk of bias. Lack of blinding was the most frequent source of bias. Treatment duration was six to 12 months. Forty-eight studies provided no usable or retrievable data, i.e. lack of separate data for hirsute women, conference proceedings, and losses to follow-up above 40%.Primary outcomes, 'participant-reported improvement of hirsutism' and 'change in health-related quality of life', were addressed in few studies, and adverse events in only half. In most comparisons there was insufficient evidence to determine if the number of reported adverse events differed. These included known adverse events: gastrointestinal discomfort, breast tenderness, reduced libido, dry skin (flutamide and finasteride); irregular bleeding (spironolactone); nausea, diarrhoea, bloating (metformin); hot flushes, decreased libido, vaginal dryness, headaches (gonadotropin-releasing hormone (GnRH) analogues)).Clinician's evaluation of hirsutism and change in androgen levels were addressed in most comparisons, change in body mass index (BMI) and improvement of other clinical signs of hyperandrogenism in one-third of studies.The quality of evidence was moderate to very low for most outcomes.There was low quality evidence for the effect of two oral contraceptive pills (OCPs) (ethinyl estradiol + cyproterone acetate versus ethinyl estradiol + desogestrel) on change from baseline of Ferriman-Gallwey scores. The mean difference (MD) was -1.84 (95% confidence interval (CI) -3.86 to 0.18).There was very low quality evidence that flutamide 250 mg, twice daily, reduced Ferriman-Gallwey scores more effectively than placebo (MD -7.60, 95% CI -10.53 to -4.67 and MD -7.20, 95% CI -10.15 to -4.25). Participants' evaluations in one study with 20 participants confirmed these results (risk ratio (RR) 17.00, 95% CI 1.11 to 259.87).Spironolactone 100 mg daily was more effective than placebo in reducing Ferriman-Gallwey scores (MD -7.69, 95% CI -10.12 to -5.26) (low quality evidence). It showed similar effectiveness to flutamide in two studies (MD -1.90, 95% CI -5.01 to 1.21 and MD 0.49, 95% CI -1.99 to 2.97) (very low quality evidence), as well as to finasteride in two studies (MD 1.49, 95% CI -0.58 to 3.56 and MD 0.40, 95% CI -1.18 to 1.98) (low quality evidence).Although there was very low quality evidence of a difference in reduction of Ferriman-Gallwey scores for finasteride 5 mg to 7.5 mg daily versus placebo (MD -5.73, 95% CI -6.87 to -4.58), it was unlikely it was clinically meaningful. These results were reinforced by participants' assessments (RR 2.06, 95% CI 0.99 to 4.29 and RR 11.00, 95% CI 0.69 to 175.86). However, finasteride showed inconsistent results in comparisons with other treatments, and no firm conclusions could be reached.Metformin demonstrated no benefit over placebo in reduction of Ferriman-Gallwey scores (MD 0.05, 95% CI -1.02 to 1.12), but the quality of evidence was low. Results regarding the effectiveness of GnRH analogues were inconsistent, varying from minimal to important improvements.We were unable to pool data for OCPs with cyproterone acetate 20 mg to 100 mg due to clinical and methodological heterogeneity between studies. However, addition of cyproterone acetate to OCPs provided greater reductions in Ferriman-Gallwey scores.Two studies, comparing finasteride 5 mg and spironolactone 100 mg, did not show differences in participant assessments and reduction of Ferriman-Gallwey scores (low quality evidence). Ferriman-Gallwey scores from three studies comparing flutamide versus metformin could not be pooled (I² = 62%). One study comparing flutamide 250 mg twice daily with metformin 850 mg twice daily for 12 months, which reached a higher cumulative dosage than two other studies evaluating this comparison, showed flutamide to be more effective (MD -6.30, 95% CI -9.83 to -2.77) (very low quality evidence). Data showing reductions in Ferriman-Gallwey scores could not be pooled for four studies comparing finasteride with flutamide as the results were inconsistent (I² = 67%).Studies examining effects of hypocaloric diets reported reductions in BMI, but which did not result in reductions in Ferriman-Gallwey scores. Although certain cosmetic measures are commonly used, we did not identify any relevant RCTs. AUTHORS' CONCLUSIONS Treatments may need to incorporate pharmacological therapies, cosmetic procedures, and psychological support. For mild hirsutism there is evidence of limited quality that OCPs are effective. Flutamide 250 mg twice daily and spironolactone 100 mg daily appeared to be effective and safe, albeit the evidence was low to very low quality. Finasteride 5 mg daily showed inconsistent results in different comparisons, therefore no firm conclusions can be made. As the side effects of antiandrogens and finasteride are well known, these should be accounted for in any clinical decision-making. There was low quality evidence that metformin was ineffective for hirsutism and although GnRH analogues showed inconsistent results in reducing hirsutism they do have significant side effects.Further research should consist of well-designed, rigorously reported, head-to-head trials examining OCPs combined with antiandrogens or 5α-reductase inhibitor against OCP monotherapy, as well as the different antiandrogens and 5α-reductase inhibitors against each other. Outcomes should be based on standardised scales of participants' assessment of treatment efficacy, with a greater emphasis on change in quality of life as a result of treatment.
Collapse
Affiliation(s)
- Esther J van Zuuren
- Leiden University Medical CenterDepartment of DermatologyPO Box 9600B1‐QLeidenNetherlands2300 RC
| | | | - Ben Carter
- King's College London; Institute of Psychiatry, Psychology & NeuroscienceBiostatistics and Health InformaticsDenmark HillLondonUK
| | - Nikolaos Pandis
- University of BernDepartment of Orthodontics and Dentofacial OrthopedicsFreiburgstr. 7BernSwitzerlandCH‐3010
| |
Collapse
|
15
|
Laganà AS, Palmara V, Granese R, Ciancimino L, Chiofalo B, Triolo O. Desogestrel versus danazol as preoperative treatment for hysteroscopic surgery: a prospective, randomized evaluation. Gynecol Endocrinol 2014; 30:794-7. [PMID: 24919887 DOI: 10.3109/09513590.2014.929658] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
The aim of this single-center, prospective, randomized, parallel-group study was to compare desogestrel and danazol as preoperative endometrial preparation for hysteroscopic surgery. We enrolled 200 consecutive eligible patients, in reproductive age, with endouterine diseases. Pre- and post-treatment characterization of endometrium was performed by hysteroscopic visual observation and histologic confirmation. The enrolled patients were randomly assigned to two groups: 100 were treated with 75 μg of desogestrel/die, 100 with 100 mg of danazol/die, both orally for 5 weeks, starting on Day 1 of menstruation. We recorded intraoperative data (cervical dilatation time, operative time, infusion volume and severity of bleeding) and drugs' side effects. Post-treatment comparison of endometrial patterns showed a significant more marked effect of desogestrel, respect to danazol, in atrophying endometrium ("normotrophic non-responders" versus "hypotrophic"-"atrophic", p = 0.031). Intraoperative data showed no significant differences between the two groups for cervical dilatation time (p = 0.160), while in the desogestrel group we found a significant reduction of operative time (p = 0.020), infusion volume (p = 0.012), and severity of bleeding (p = 0.004). Moreover, desogestrel caused less side effects (p = 0.031). According to our data analysis, desogestrel showed most marked effect in inducing endometrial atrophy, allowed a better intraoperative management and caused less side effects during treatment.
Collapse
Affiliation(s)
- Antonio Simone Laganà
- Department of Pediatric, Gynecological, Microbiological and Biomedical Sciences, University of Messina , Messina , Italy
| | | | | | | | | | | |
Collapse
|
16
|
Leelaphiwat S, Jongwutiwes T, Lertvikool S, Tabcharoen C, Sukprasert M, Rattanasiri S, Weerakiet S. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res 2014; 41:402-10. [PMID: 25319761 DOI: 10.1111/jog.12543] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Accepted: 07/31/2014] [Indexed: 11/30/2022]
Abstract
AIM To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS. METHODS This was a randomized clinical study. Eighteen women in groups A and B received medications for three cycles. Acne score, androgens and metabolic parameters were assessed before and after treatment. RESULTS One and two women in groups A and B, respectively, were excluded from the study. Both groups had significantly decreased acne score and free androgen index, and increased sex hormone-binding globulin levels. Cholesterol and high-density lipoprotein were significantly increased in group B, and androstenedione was significantly decreased in group A. The regular withdrawal bleeding was obtained in both groups. CONCLUSION Both regimens had quite similar efficacy on hyperandrogenism after three cycles of therapy and without any changes in metabolic parameters.
Collapse
Affiliation(s)
- Supatra Leelaphiwat
- Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
OBJECTIVE To evaluate the risks and benefits of third-generation oral contraceptives. DATA SOURCES A MEDLINE search was done for English language articles published from 1985 through 1998 relating to the side-effect profile of third-generation oral contraceptives or their association with cardiovascular or thromboembolic disease. All articles containing original data were included. DATA SYNTHESIS The risk of venous thromboembolism appears to be 1.5- to 2.7-fold greater in users of third-generation, compared with second-generation, oral contraceptives. Compared with nonusers, women who use third-generation oral contraceptives may have a 4.8- to 9.4-fold greater risk of venous thromboembolism. Users of third-generation oral contraceptives do not appear to have an increased risk of myocardial infarction compared with nonusers and may have risk of myocardial infarction of 0.26 to 0.7 compared with second-generation users. Whether third-generation oral contraceptives are associated with a decreased stroke risk is still not clear. CONCLUSIONS Although third-generation oral contraceptives most likely increase a user's risk of venous thromboembolism, their improved side-effect profile and their possible decreased association with myocardial infarction and stroke may make them a useful new class of oral contraceptives for most women except those at increased risk of venous thrombosis.
Collapse
Affiliation(s)
- E S Leblanc
- Department of Internal Medicine, Portland Veterans Affairs Medical Center, Portland, OR, USA
| | | |
Collapse
|